Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Human Health, Environmental Comfort and Well-Being. Part 1. Engineering and Design Resources of the Bioindustry on the Way to Safe Competition with the Resources of Natural Biocenoses and Health-Saving Systems
Suchkov, Sergey , Abe, Hirokazu , Polyakova, V. S. , Глинушкин, А. П. , Tan, Ming , Abe, H., Murphy, S., Smith, D., Scherman, Daniel , Barach, Paul Randall , Terent'ev, Alexander Olegovich , Tan, M., Suvorov, A. N.

Mayo Clinic

Uspehi sovremennoj biologii | December 18, 2024 | Volume: 144 | Issue: 3 | Pages: 291-313

10.31857/s0042132424030033 Get It

Everyone has the right to the highest attainable standard of health, and modern preventive, preventive and rehabilitative manipulations promote health and well-being. Thanks to a number of fundamental projects on the study of human health at various levels (genomic, proteomic, and metabolomic), and molecular mechanisms of the development of pathological conditions, there has been a great leap in the field of applied sectors of industrial biotechnology, including segments of the pharmaceutical and food industries, significantly replenished health-saving resources and improved the quality of life of the population. This article will review the advanced achievements of fundamental and applied research, as well as promising areas of the bioindustry.
Estimating surgical blood loss: A review of current strategies in various clinical settings
Stoker, Alexander, Binder, William J. , Frasco, Peter E. , Morozowich, Steven T., Bettini, Layne M, Murray, Andrew W. , Fah, Megan K, Gorlin, Andrew , Stoker, Alex D , Binder, Will J , Gorlin, Andrew W, Bettini, Layne M., Fah, Megan K.

Mayo Clinic

SAGE Open Medicine | December 17, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/20503121241308302 | PMID 39691865 Get It

The estimation of surgical blood loss is routinely performed during and after surgical procedures and has morbidity and mortality implications related to the risk of under- and over-resuscitation. The strategies for estimating surgical blood loss include visual estimation, the gravimetric method, the colorimetric method, formula-based methods, and other techniques (e.g., cell salvage). Currently, visual estimation continues to be the most widely used technique. In addition, unique considerations exist when these techniques are applied to various clinical settings such as massive transfusion, cardiac surgery, and obstetrics. Ultimately, when using estimated surgical blood loss to guide perioperative fluid management and transfusion thresholds, it is also important to mitigate the risks associated with resuscitation by targeting a goal-directed fluid therapy approach by utilizing markers of fluid-responsiveness to optimize stroke volume (cardiac output) and delivery of oxygen.
Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial
Schwarz, Anne , Feldman, Marc D., Le, Vu , Dawson, Jesse, Francisco, Gerard E., Wolf, Steven L., Dixit, Anand, Alexander, Jen , Ali, Rushna , Brown, Benjamin L. , Feng, Wuwei , DeMark, Lou , Hochberg, Leigh R. , Majid, Arshad , O’Dell, Michael W. , Redgrave, Jessica, Cramer, Steven C. , Feng, Wuwei , Cramer, Steven C , Dawson, Jesse , Liu, Charles Y. , Francisco, Gerard E. , Kautz, Steven A. , Turner, Duncan L. , Kimberley, Teresa Jacobson

Mayo Clinic

Annals of Neurology | December 16, 2024 | Volume: 97 | Issue: 4 | Pages: 709-719

10.1002/ana.27156 | PMID 39676623 Get It

ObjectiveVagus nerve stimulation (VNS) paired with rehabilitation therapy improved motor status compared to rehabilitation alone in the phase III VNS‐REHAB stroke trial, but treatment response was variable and not associated with any clinical measures acquired at baseline, such as age or side of paresis. We hypothesized that neuroimaging measures would be associated with treatment‐related gains, examining performance of regional injury measures versus global brain health measures in parallel with clinical measures.MethodsBaseline magnetic resonance imaging (MRI) scans in the VNS‐REHAB trial were used to derive regional injury measures (extent of injury to corticospinal tract, the primary regional measure; plus extent of injury to precentral gyrus and postcentral gyrus; lesion volume; and lesion topography) and global brain health measures (degree of white matter hyperintensities, the primary global brain measure; plus volumes of cerebrospinal fluid, cortical gray matter, white matter, each thalamus, and total brain). Eight clinical measures assessed at baseline were also evaluated (treatment group, age, race, gender, paretic side, pre‐stroke dominant hand, time since stroke, and baseline Fugl‐Meyer upper extremity score). Bivariate analyses compared each measure with the primary trial end point (change in Fugl‐Meyer upper extremity score from baseline to end of 6 weeks of treatment) across all subjects, with secondary analyses examining trial groups separately.ResultsMRIs were available from 80 patients (age = 59.8 ± 9.5 years, 29 women). Across all patients, less white matter hyperintensities (r = −0.25, p = 0.028) at baseline was associated with larger Fugl‐Meyer score change. In the VNS group, less white matter hyperintensities (r = −0.37, p = 0.018) and larger ipsilesional thalamus volume (r = 0.33, p = 0.046) were each associated with larger Fugl‐Meyer score change. Analysis of covariance (ANCOVA) analyses tested the interaction that each baseline measure had with treatment group and found that the model examining white matter hyperintensities had a significant interaction term, indicating 2.3 less change in Fugl‐Meyer Upper Extremity (FM‐UE) points in the VNS group relative to the control group for each point increase in modified Fazekas scale.InterpretationNeuroimaging measures are associated with extent of gains on the primary endpoint of a phase III stroke recovery trial. Among the neuroimaging measures examined, a measure of global brain health (extent of white matter hyperintensities) was better at explaining the change in arm impairment as compared with measures of regional injury; this was true when examining all study subjects as well as only those in the VNS group and is consistent with the global mechanism of action that VNS has throughout the cerebrum. Future studies can evaluate additional measures that further predict response to VNS therapy. The current findings suggest that individual patient neuroimaging results may be useful for a personalized medicine approach to stroke recovery therapeutics. ANN NEUROL 2025;97:709–719
Stretch & exercise education improves pain levels in under-resourced collegiate club lacrosse players
Gawrys, Steven P. , Wilson, Holly, Matthias, Alexander K., Roush, Andrew J. , VandeMerwe, David C., Parker, Lawsen M., Starr, Evan G. , Wong, Westin J. , Enslow, Ryan , Wilde, Ben, Zapata, Isain , Pickett, Brent, Wilson, Holly

Mayo Clinic

The Physician and Sportsmedicine | December 14, 2024 | Volume: 53 | Issue: 3 | Pages: 230-237

10.1080/00913847.2024.2443389 | PMID 39673554 Get It

Sunitinib induced glomerular thrombotic microangiopathy in a patient with refractory pancreatic neuroendocrine tumour
Khan, Aisha , Gangelhoff, Margarita Consing, Moubarak, Simon , Nooruddin, Karim, Alexander, Mariam P., Alexander, Mariam P. , Herrmann, Sandra, Alexander, Mariam P , Herrmann, Sandra M.

Mayo Clinic

Journal of Clinical Pathology | December 14, 2024 | Volume: 78 | Issue: 5 | Pages: 357-358

10.1136/jcp-2024-209851 | PMID 39674583 Get It

An international Delphi consensus on patient preparation for metabolic and bariatric surgery
Clyde, Danielle , Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Catalain, Copaescu, Clare, Ken , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Ghanem, Omar M. , Hopkins, George, Kothari, Shanu N. , Kow, Lilian , Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Saliminen, Paulina, Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Tahrani, Abd A. , Voon, Kelvin , Welbourn, Richard , Lamb, Peter , Mahawar, Kamal , Yang, Wah , Salminen, Paulina , Kermansaravi, Mohammad , Zerrweck, Carlos , Yang, Wah , Byrne, James Patrick , Cameron, David, Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Husain, Farah Anwari , Joyce, Brian, Miras, Alexander Dimitri , Moussa, Osama , Neto, Manoel Galvão , Parmar, Chetan D. , Peterli, Ralph , Stenberg, Erik , Vilallonga, Ramón , Robertson, Andrew G.

Mayo Clinic

Clinical Obesity | December 14, 2024 | Volume: 15 | Issue: 2 | Pages: No page available

10.1111/cob.12722 | PMID 39673462 Get It

SummaryGlobal obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m2), is performed globally over 500 000 times annually, offering significant metabolic benefits beyond weight loss. However, varying eligibility criteria globally impact patient care and healthcare resources. Updated in 2022, ASMBS and IFSO guidelines aim to standardise MBS indications, reflecting current understanding and emphasising comprehensive preoperative assessments. Yet, clinical variability persists, necessitating consensus‐based recommendations. This modified Delphi study engaged 45 global experts to establish consensus on perioperative management in MBS. Experts selected from bariatric societies possessed expertise in MBS and participated in a two‐round Delphi protocol. Consensus was achieved on 90 of 169 statements (53.3%), encompassing multidisciplinary team composition, patient selection criteria, preoperative testing, and referral pathways. The agreement highlighted the critical role of comprehensive preoperative assessments and the integration of healthcare professionals in MBS. These findings offer essential insights to standardise perioperative practices and advocate for evidence‐based guidelines in MBS globally. The study underscores the need for unified protocols to optimise outcomes and guide future research in MBS.
Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer
Huang, Chen , Srinivasan, Ramakrishnan Rajaram , Lewis, Alaina , Sallas, Christina , Zhao, Na , Cao, Jin , Pilcher, Jacob B., Moon, Chang In, Liao, Yuxing , Rimawi, Mothaffar F. , Malovannaya, Anna , Li, Shunqiang , Kraushaar, Daniel C. , Goetz, Matthew P., Boughey, JC , Wang, Liewei, Kalari, Krishna R., Suman, Vera J., Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, F, Welm, Bryan E. , Welm, Alana L. , Zhang, Bing , Lei, Jonathan T , Zhao, Na , Wen, Bo , Rimawi, Mothaffar , Lei, Jonathan T. , Dobrolecki, Lacey E. , Vasaikar, Suhas , Landua, John David , Pilcher, Jacob B. , Hilsenbeck, Susan Galloway , Ellis, Matthew J. , Petrosyan, Varduhi, Li, Kai shang , Saltzman, Alexander B. , Jain, Antrix , Wulf, Gerburg M. , Marangoni, Elisabetta , Wang, Tao , Goetz, Matthew P. , Damodaran, Senthil , Zheng, Xiaofeng , Meric‐Bernstam, Funda , Echeverria, Gloria Vittone , Anurag, Meenakshi , Chen, Xi , Lewis, Michael T.

Mayo Clinic

No container title available | December 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.12.09.627518 | PMID 39713418 Get It

Abstract Chemotherapy regimens for triple-negative breast cancer (TNBC) combine agents without knowing which agents drive response. Consequently, predictors derived from multi-agent regimens cannot be assumed to generalize to individual drugs or other regimens, motivating development of treatment-matched predictors. Here, we used TNBC patient-derived xenografts (PDXs) treated with carboplatin, docetaxel, or the combination to deconvolute drug-specific responses and identify associated molecular features. Combination treatment rarely improved upon the best single agent, with enhanced responses in only 13% of PDXs and antagonism in a comparable fraction. Proteogenomic analyses identified high cytokeratin-5 (KRT5) as a general marker of chemotherapy responsiveness and KRT5 immunohistochemistry discriminated responsive PDXs (AUROC, 0.83). To train treatment-specific predictors, we integrated these data with independent PDX and clinical cohorts with responses assessed after anthracycline-free platinum, taxane, or platinum-taxane therapy, ensuring response corresponded to the modeled treatment. Four feature selection strategies yielded largely nonoverlapping biomarker panels converging on treatment-relevant pathways. On independent test data, RNA-based predictors of complete response (CR) to platinum-based (carboplatin or cisplatin) and taxane-based (docetaxel or paclitaxel) chemotherapy achieved AUROCs of 0.80 and 0.86, respectively. For platinum-taxane regimens (carboplatin plus docetaxel or paclitaxel), proteomic-guided feature selection generated a 10-biomarker, protein- informed RNA predictor of pathologic complete response (pCR) that outperformed RNA-only feature selection and achieved an AUROC of 0.85 in an independent clinical cohort, while retaining practicality as an RNA-based assay. Treatment-matched integration of multi-omic PDX and clinical datasets provides a framework for chemotherapy-specific predictors with clinically relevant performance, supporting biomarker-guided precision selection and treatment optimization for patients with TNBC. Statement of significance Integration of multi-omic data from patient-derived xenografts with treatment-matched clinical cohorts yielded three retrospectively validated predictors of platinum, taxane, and platinum+taxane response, enabling biomarker-guided chemotherapy selection for patients with triple-negative breast cancer.
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
Haque, Tamanna , King, Zoe, Kishtagari, Ashwin , Madanat, Yazan F. , Borate, Uma , Slosky, David, Patnaik, Mrinal S., Bick, Alexander G., Verma, Amit , Jaiswal, Siddhartha , Kishtagari, Ashwin , Madanat, Yazan , Steensma, David P , Savona, Michael R , Jaiswal, Siddhartha , Shastri, Aditi , Desai, Pinkal , Xie, Zhuoer , Hammond, Danielle , Abaza, Yasmin , Silver, Alexander J. , Singh, Abhay , Heimlich, Jonathan Brett , Bolton, Kelly L. , Patnaik, Mrinal S., Bick, Alexander G. , Steensma, David P. , Savona, Michael R.

Mayo Clinic

British Journal of Haematology | December 10, 2024 | Volume: 206 | Issue: 2 | Pages: 416-427

10.1111/bjh.19925 | PMID 39653653 Get It

SummaryThe age‐associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH‐focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021.
Aerobic Capacity of Adults With Fontan Palliation: Disease-Specific Reference Values and Relationship to Outcomes
Egbe, Alexander C. , Ali, Ahmed E. , Miranda, William R. , Connolly, Heidi M. , Borlaug, Barry A. , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | December 9, 2024 | Volume: 18 | Issue: 2 | Pages: No page available

10.1161/circheartfailure.124.011981 | PMID 39648896 Get It

BACKGROUND: Patients with Fontan palliation have reduced aerobic capacity because of impaired cardiac, pulmonary, and skeletal muscle function. However, the assessment of aerobic capacity in this population still relies on comparisons with people without cardiovascular disease rather than comparison with the expected aerobic capacity of other Fontan patients. The purpose of this study was to determine the expected aerobic capacity of adults with Fontan palliation. METHODS: Adults with Fontan palliation who underwent a cardiopulmonary exercise test at Mayo Clinic (2003–2023) were stratified into quartiles based on the predicted peak oxygen consumption (VO 2 ). We assessed the correlates of predicted peak VO 2 and the relationship between predicted peak VO 2 quartiles and cardiovascular outcomes (death/transplant). RESULTS: Of 323 patients (age, 29±9 years; 177 [55%] men), the median peak VO 2 was 19.1 (15.2–23.9) mL/kg per minute, and this corresponds to a predicted peak VO 2 of 51% (range, 19–88; interquartile range, 41–62). After multivariable adjustments, the correlates of predicted peak VO 2 were body mass index (β±SE, −2.61±0.95; 2.61% decrease in predicted peak VO 2 per 5 kg/m 2 increase in body mass index; P =0.009), systemic saturation (β±SE, 3.65±0.85; 3.65% increase in predicted peak VO 2 per 5% increase in oxygen saturation; P <0.001), and Fontan pressure (β±SE, −1.24±0.22; 1.24% decrease in predicted peak VO 2 per 1 mm Hg increase in Fontan pressures; P <0.001). There was a 47% increase in the risk for death/transplant from a higher predicted peak VO 2 quartile to the next lower quartile (adjusted hazard ratio, 1.47 [95% CI, 1.09–2.05]; P =0.01). CONCLUSIONS: The results of the current study would help calibrate the interpretation of exercise test data in adults with Fontan palliation and improve risk stratification in this population. It also underscores the need to maintain normal Fontan hemodynamics and body weight, which are important determinants of aerobic capacity.
The Degree of Pre-Operative Osteoarthritis is Associated with Outcome Following THA
Hinde, Yoshio, Austin, Roman, Mavromatis, Alexander, Kashanian, Koorosh , Mavromatis, Alexander, Bingham, Joshua S. , Grammatopoulos, George

Mayo Clinic

No container title available | December 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5363527/v1 Get It

Abstract Introduction: Total hip arthroplasty (THA) is increasingly used in less severe cases of hip osteoarthritis (OA).This paper aimed to determine 1) The prevalence of different degrees of OA before THA, 2) The association of pre-operative OA severity with the severity of baseline symptoms and 3) The association of pre-operative OA severity with outcomes post-THA. Methods: A retrospective study of a prospective database of all THAs at two tertiary academic centers between 2020 and 2021 was conducted. There were 803 patients in the database, with 109 being excluded due to incomplete data. There were 694 patients included, and the mean age and body mass index were 64.50±12.80 years and 28.45±5.90 kg/m2, respectively. Most patients were women (n=361; 52.0%). Radiographic analysis was performed to assess the degree of hip OA with the Tönnis grade (0 – 3; no OA – complete degradation). Patients had pre-operative patient-reported outcome measures (PROMs) of hip function via the Oxford Hip Score (OHS) and their overall well-being via the EQ-5D-5L, with follow-up and post-operative PROMs 12 months after surgery. Data analysis was performed using SPSS (IBM, Armonk, NY). Results: There were no differences in pre-operative OHS between Tönnis groups (18±6.26, n=14 in Tönnis 1, 21.19±8.27, n=260 in Tönnis 2 and 18.18±7.09, n=420 in Tönnis 3, p=0.14) After one year, the increase in OHS was 18.03±11.95, 18.32±10.96, and 24.32±9.98, respectively for Tönnis 1,2, and 3 (p<0.001). Thus, the percentage meeting the patient acceptable symptom state (PASS) was 57.1%, 60.8% and 72.6%. One year EQ-5D-5L was also highest in Tönnis 3 (47.5 ± 4.03, 79.6 ± 13.25 and 82.12 ± 11.67, p<0.001). Conclusion: The highest-grade OA before THA was correlated with the greatest improvements in hip function and quality of life. This study demonstrates that a conservative approach and re-education should be attempted in patients who have an absence of advanced radiographic OA.